New study aims to find which MS drug better fights fatigue

NCT ID NCT06843382

Not yet recruiting Knowledge-focused Sponsor: TC Erciyes University Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated Jun 16, 2026 · Updated 27 times

Summary

This study will follow 100 adults with multiple sclerosis who are starting either teriflunomide or dimethyl fumarate as part of their routine care. Over 12 months, researchers will measure how well participants can walk and think during sustained activities, along with their reported fatigue and quality of life. The goal is to see if one drug helps more with physical and mental tiredness, helping patients and doctors make better treatment choices.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Erciyes University

Kayseri, Turkey (Türkiye)

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS